AU2019262612B2 - Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin - Google Patents

Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin Download PDF

Info

Publication number
AU2019262612B2
AU2019262612B2 AU2019262612A AU2019262612A AU2019262612B2 AU 2019262612 B2 AU2019262612 B2 AU 2019262612B2 AU 2019262612 A AU2019262612 A AU 2019262612A AU 2019262612 A AU2019262612 A AU 2019262612A AU 2019262612 B2 AU2019262612 B2 AU 2019262612B2
Authority
AU
Australia
Prior art keywords
centhaquin
blood
salt
shock
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019262612A
Other languages
English (en)
Other versions
AU2019262612A1 (en
Inventor
Anil Gulati
Bhawna KATIA
Manish Lavhale
Abhishek Kumar Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmazz Inc
Midwestern University Glendale
Original Assignee
Midwestern University Downers Grove
Pharmazz Inc
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University Downers Grove, Pharmazz Inc, Midwestern University Glendale filed Critical Midwestern University Downers Grove
Publication of AU2019262612A1 publication Critical patent/AU2019262612A1/en
Application granted granted Critical
Publication of AU2019262612B2 publication Critical patent/AU2019262612B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019262612A 2018-05-03 2019-05-03 Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin Active AU2019262612B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666675P 2018-05-03 2018-05-03
US62/666,675 2018-05-03
IN201841019588 2018-05-25
IN201841019588 2018-05-25
PCT/US2019/030652 WO2019213558A1 (en) 2018-05-03 2019-05-03 Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin

Publications (2)

Publication Number Publication Date
AU2019262612A1 AU2019262612A1 (en) 2020-11-26
AU2019262612B2 true AU2019262612B2 (en) 2025-04-03

Family

ID=68386694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019262612A Active AU2019262612B2 (en) 2018-05-03 2019-05-03 Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin

Country Status (9)

Country Link
US (1) US20210169978A1 (https=)
EP (2) EP3813942B1 (https=)
JP (1) JP7458032B2 (https=)
CN (1) CN112469474A (https=)
AU (1) AU2019262612B2 (https=)
BR (1) BR112020022395A2 (https=)
ES (1) ES2978951T3 (https=)
PL (1) PL3813942T3 (https=)
WO (1) WO2019213558A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
JP2024517334A (ja) * 2021-05-11 2024-04-19 ファーマズ，インコーポレイテッド コロナウイルス疾患（ｃｏｖｉｄ－１９）における急性呼吸窮迫症候群（ａｒｄｓ）の治療のための医薬組成物及び方法
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss
IN202411028038A (https=) * 2024-04-04 2025-05-23

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019644A1 (fr) * 1991-04-24 1992-11-12 Banyu Pharmaceutical Co., Ltd. Peptide vasodilatateur
US20150250782A1 (en) * 2012-08-31 2015-09-10 Pharmazz, Inc. Methods and Compositions for Hypotensive Resuscitation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578709C (en) * 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
AU2008237062A1 (en) 2007-04-10 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted deuterium enriched thiophenes for the treatment of hypertension
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
AU2010241564B2 (en) * 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
AU2014287427B2 (en) 2013-07-08 2019-11-21 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019644A1 (fr) * 1991-04-24 1992-11-12 Banyu Pharmaceutical Co., Ltd. Peptide vasodilatateur
US20150250782A1 (en) * 2012-08-31 2015-09-10 Pharmazz, Inc. Methods and Compositions for Hypotensive Resuscitation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE MIGUEL CARMEN ET AL: "Endothelin receptor-specific control of endoplasmic reticulum stress and apoptosis in the kidney", SCIENTIFIC REPORTS, vol. 7, no. 1, 1 March 2017 (2017-03-01). DOI: 10.1038/srep43152 *

Also Published As

Publication number Publication date
EP3813942A1 (en) 2021-05-05
JP2021523125A (ja) 2021-09-02
EP3813942A4 (en) 2022-01-19
AU2019262612A1 (en) 2020-11-26
WO2019213558A1 (en) 2019-11-07
CA3099128A1 (en) 2019-11-07
US20210169978A1 (en) 2021-06-10
CN112469474A (zh) 2021-03-09
PL3813942T3 (pl) 2024-07-22
JP7458032B2 (ja) 2024-03-29
ES2978951T3 (es) 2024-09-23
EP3813942B1 (en) 2024-04-17
BR112020022395A2 (pt) 2021-04-13
EP4364811A2 (en) 2024-05-08
EP4364811A3 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
AU2019262612B2 (en) Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
US20230310420A1 (en) Methods and compositions for hypotensive resuscitation
US20200375953A1 (en) Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
KR100445946B1 (ko) 폐고혈압 치료법
Wall Endocrine disease
Llach et al. Effect of dipyridamole on kidney function in cirrhosis
CA3099128C (en) Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
WO2021037212A9 (zh) 用于对抗代谢疾病的组合物及其用途
JP7809731B2 (ja) 全身性硬化症の予防または治療用薬学的組成物
TW202404627A (zh) 使用cd39、重組cd39用於急性器官損傷的治療
AU2017249459A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
Briyal et al. Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin.
AU2015203036A1 (en) Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
Cetin et al. The Cardiovascular System: Implications of Obesity on the Body System and Resolution of Disease Processes Following Bariatric Surgery
JP2019513727A (ja) レンバチニブ及びエベロリムスを用いた腎細胞癌の治療
RU2785893C2 (ru) Лечение почечно-клеточной карциномы ленватинибом и эверолимусом
Cordingley et al. Renal rescue–management of impending renal failure
EA044878B1 (ru) L-трийодтиронин (t3) для применения при ослаблении микрососудистой окклюзии

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)